HCPCS Code G2082: Billing Guide for Spravato (56 mg or Less)

HCPCS code G2082 is used to report an outpatient visit that includes the evaluation, management, and administration of up to 56 mg of esketamine (Spravato) nasal spray, along with the required two-hour post-administration observation period.

G2082 applies only to established patients treated in a REMS-certified clinical setting and bundles the professional service, medication (up to 56 mg), and clinical supervision required under the Spravato Risk Evaluation and Mitigation Strategy (REMS) program.

This article explains G2082 billing rules, bundled services, documentation requirements, reimbursement rates, common errors, and 2026 Spravato coding updates to support compliant reimbursement.

Official Description of HCPCS Code G2082

According to the Centers for Medicare & Medicaid Services (CMS), the official description of G2082 is:

“Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of up to 56 mg of esketamine nasal self-administration, includes 2 hours post-administration observation.”

What Is the Difference Between G2082 and G2083?

The distinction between G2082 and G2083 is based on total dosage administered during the session.

Code	Esketamine Dose	Typical Use Case
G2082	Up to 56 mg	Induction or lower-dose maintenance
G2083	84 mg	Standard maintenance dosing

Both codes include the same evaluation, supervision, and two-hour observation requirements. However, G2083 reimburses at a higher rate to account for the additional 28 mg of medication. Using the wrong code is a common cause of Spravato-related billing denials

What Services Are Included in G2082?

G2082 represents a single, comprehensive treatment session and includes:

• Face-to-face evaluation by a physician or qualified healthcare professional
• Administration of up to 56 mg of esketamine nasal spray
• Continuous clinical supervision
• Mandatory 120-minute post-dose monitoring

Separate billing for these bundled components is not allowed when G2082 is reported.

Reimbursement Rates For G2082 (2026)

Medicare reimburses HCPCS code G2082 at a national average rate of $952.59. Major private payers, including BCBS, UHC, Aetna, and Cigna, reimburse an average of approximately $857 for G2082.

Reimbursement rates may vary by payer, contract terms, geographic location, and Medicare Administrative Contractor (MAC), so check the specific payer fee schedule before Spravato billing.

What Are the Clinical Requirements to Bill G2082?

To bill G2082, the encounter must meet all criteria established by the CMS. Required Conditions

1. Established patient status
2. Face-to-face E/M service performed by a physician or qualified healthcare professional
3. Esketamine dosage not exceeding 56 mg
4. Full two-hour post-administration observation period

During observation, providers must monitor for adverse effects such as sedation, dissociation, and elevated blood pressure. Failure to meet any of these conditions can result in claim denial.

What Documentation Is Required to Support G2082?

Accurate documentation is essential to meet Spravato REMS program requirements and to ensure compliance during audits. The following documentation must be maintained to appropriately support billing for HCPCS code G2082:

Incomplete documentation increases denial risk.

What Are Common G2082 Billing Errors?

G2082 claims are denied due to preventable issues, including:

• Wrong dosage coding: Using G2082 when more than 56 mg of esketamine is administered. Doses above 56 mg must be billed with G2083.
• Missing or unclear observation time: Failure to document a full 120-minute post-dose observation period with clear start and end times.
• Billing for new patients: G2082 applies only to established patients. Using it for new patients violates CMS rules.
• Unbundling included services: Billing separate E/M or prolonged service codes with G2082 is not allowed under Centers for Medicare & Medicaid Services guidelines.
• Insufficient REMS or diagnosis support: Missing REMS certification documentation or inadequate ICD-10-CM diagnosis coding increases denial and audit risk.

Best Practices for Billing G2082

Here are some best practices for billing G2082:

• Verify patient eligibility: Confirm established patient status before billing.
• Confirm dose before coding: Use G2082 only for sessions involving 56 mg or less of esketamine.
• Document observation: Record administration time and the full two-hour monitoring period, including discharge time.
• Follow REMS documentation standards: Include provider supervision, vital signs, and mental status monitoring.
• Avoid unbundling: Do not bill separate E/M or prolonged services unless allowed by the payer.
• Check payer-specific rules: While Medicare follows strict bundling, commercial payer requirements may vary.

What Changed for Spravato Billing in 2026?

Beginning January 1, 2026, esketamine coding was refined to better separate drug costs from professional services. Key 2026 updates are given below:

• Temporary drug code S0013 is discontinued
• New HCPCS drug code J0013 (Esketamine, nasal spray, 1 mg) has been introduced
• G2082 and G2083 remain valid for bundled professional services

Under Medicare, the bundled G-code model continues to be the preferred “buy-and-bill” approach. Some commercial payers may require separate reporting of:

• Drug supply using J0013
• Professional services using E/M and prolonged service codes

Always verify payer-specific rules before billing.

Final Words

HCPCS code G2082 is the correct billing code for Spravato sessions involving 56 mg or less of esketamine. It bundles evaluation, administration, and mandatory monitoring into one outpatient service. Proper dosage selection, strict documentation, and payer verification are essential for compliant reimbursement, as 2026 coding changes take effect.